Key result
Auricular transcutaneous vagus nerve stimulation is proposed as a potential non-pharmacological add-on intervention to ameliorate affective symptoms and cognitive decline in long COVID.
Why the study?
Long COVID causes cognitive deficits and affective symptoms potentially linked to persistent brainstem dysfunction and disrupted vagal signaling, highlighting the need for add-on non-pharmacological interventions like atVNS.
Does auricular transcutaneous vagus nerve stimulation improve cognitive and affective symptoms in patients with long COVID?
Does auricular transcutaneous vagus nerve stimulation improve cognitive and affective symptoms in patients with long COVID?
Auricular transcutaneous vagus nerve stimulation is proposed as a potential non-pharmacological add-on therapy to improve cognitive and affective symptoms in patients with long COVID.
May support non-pharmacological options for long COVID symptoms; leaves open confirmation in randomized trials.
Long COVID, the postviral disorder caused by COVID-19, is expected to become one of the leading causes of disability in Europe. The cognitive consequences of long COVID have been described as "brain fog" and characterized by anxiety and depression, and by cognitive deficits. Long COVID is assumed to be a complex condition arising from multiple causes, including persistent brainstem dysfunction and disrupted vagal signaling. We recommend the potential application of auricular transcutaneous vagus nerve stimulation (atVNS) as an ADD-ON instrument to compensate for the cognitive decline and to ameliorate affective symptoms caused by long COVID. This technique enhances vagal signaling by directly activating the nuclei in the brainstem, which are hypoactive in long COVID to enhance mood and to promote attention, memory, and cognitive control-factors affected by long COVID. Considering that atVNS is a non-pharmacological intervention, its ADD-ON to standard pharmaceutical agents will be useful for non-responders, making of this method a suitable tool. Given that atVNS can be employed as an ecological momentary intervention (EMI), we outline the translational advantages of atVNS in the context of accelerating the cognitive and affective recovery from long COVID.
No takes yet. Share an insight, caveat, or question.
Colzato et al. (2023) conducted a review in Long COVID. Auricular transcutaneous vagus nerve stimulation (atVNS) was evaluated. Auricular transcutaneous vagus nerve stimulation is proposed as a potential non-pharmacological add-on intervention to ameliorate affective symptoms and cognitive decline in long COVID.
Synapse has enriched 5 related papers. Consider them for comparative context: